Composition
- Active ingredients
- NINTEDANIB ESYLATE EQ 150MG BASE
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application ANDA212555.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Nintedanib
- Active substance
- nintedanib esylate
- Route
- Oral
- Dosage form
- Capsule
- Applicant
- Glenmark Pharms LTD
- Status
- Tentative approval
- FDA approval
- 26 Mar 2026
- Application
- ANDA212555-002